CAMBRIDGE, Mass., June 7, 2022 /PRNewswire/ -- Sanofi announces the opening of the company's new campus at Cambridge Crossing in Cambridge, Massachusetts. Governor Charlie Baker and Cambridge Mayor Sumbul Siddiqui plan to attend the ribbon-cutting ceremony in addition to Sanofi's CEO Paul Hudson and Executive Committee members, Global Head of Research and Development John Reed, M.D., Ph.D., and Global Head of Specialty Care Bill Sibold, for the official opening of one of the company's largest U.S. sites. The campus is designed to enhance collaboration between R&D, Medical, and the Specialty Care business unit, among others, to accelerate the development of transformative treatments for patients.
Executive Vice President, Head of Global Specialty Care, Sanofi
"Cambridge has been our home for many years. Opening our new facility in Cambridge Crossing is allowing us to bring together our employees across Massachusetts under one roof – which is an important step in facilitating the kind of collaboration needed to fulfill our purpose of chasing the miracles of science to improve people's lives."
Sanofi at Cambridge Crossing consists of two buildings, both U.S. Green Building Council LEED® Gold Certified, totaling 900,000 square feet and located at 450 Water Street and 350 Water Street. The campus incorporates state–of–the–art environmental features, including automated light dimming, CO2 sensors, and advanced heating/cooling systems, among others, to use energy and resources efficiently and to provide a healthy workspace for employees. WaterSense fixtures will harvest rainwater and create up to 60 percent water efficiency, from the EPA baseline, by using rainwater harvesting.
John Reed, M.D., Ph.D.
Executive Vice President, Global Head of Research and Development, Sanofi
"We have built an unparalleled facility for our R&D community in Cambridge with a focus on ultra-modern laboratories in close proximity to our scientific and commercial colleagues. Located in the heart of an innovation ecosystem, our new site will serve as an open space to connect our experts with key partners, including top academic research institutions and hospitals, with the goal of urgently meeting patient needs through the tireless advance of science."
Over the past 20 years, Sanofi has contributed to sustainable development of communities and, with the opening of Cambridge Crossing, we will be broadening our commitment to Just A Start, a Cambridge-based Economic Mobility Hub. For more than 50 years, Just A Start has been servicing the local community by creating access to stable housing and sustainable careers. Through the organization's Campaign for Rindge Commons, tuition-free educational programs are offered, including a Biomedical Careers Program to foster equal opportunities in the thriving Massachusetts biopharmaceutical economy.
"Massachusetts is home to a thriving health care and life sciences ecosystem and Sanofi is a crucial part of the exciting innovation and progress happening here in the Commonwealth. We are thrilled to congratulate Sanofi on the opening of this new campus, which marks a big step forward in creating a vibrant and sustainable workforce that continues to evolve with our community."
Sanofi has built an unparalleled experience in the center of Massachusetts' innovation "hotspot," and the company looks forward to retaining and attracting talent and forming new partnerships to make a difference in the surrounding community and for patients around the world.
To explore career opportunities at Sanofi, please visit www.sanofi.com/en/careers.
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Eva Schaefer-Jansen | + 33 7 86 80 56 39 | email@example.com
Arnaud Delépine | + 33 6 73 69 36 93 | firstname.lastname@example.org
Corentine Driancourt | + 33 6 40 56 92 21 | email@example.com
Felix Lauscher | + 1 908 612 7239 | firstname.lastname@example.org
Priya Nanduri | +1 617 764 6418 | email@example.com
Nathalie Pham | + 33 7 85 93 30 17 | firstname.lastname@example.org
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2021. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.